Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

21 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Changes in clinical presentation, management, and survival outcomes in patients affected by colorectal cancer following COVID-19 pandemic.
Parisi A, Giampieri R, Villani S, Magnarini A, Gelsomino F, Traisci D, Barbin F, Salvatore L, Zichi C, Di Pietro FR, Zoratto F, Lanese A, Petrillo A, Zurlo IV, Spallanzani A, D'Ostilio N, Ghidini M, Bensi M, Schietroma F, Rognone C, Panepinto O, Paparo J, Gamba T, Bisonni R, Di Lorenzo S, Daniele B, Mentrasti G, Berardi R. Parisi A, et al. Among authors: zurlo iv. Oncologist. 2024 Nov 26:oyae310. doi: 10.1093/oncolo/oyae310. Online ahead of print. Oncologist. 2024. PMID: 39591103 Free article.
Chemotherapy Rechallenge or Reintroduction Compared to Regorafenib or Trifluridine/Tipiracil for Pretreated Metastatic Colorectal Cancer Patients: A Propensity Score Analysis of Treatment Beyond Second Line (Proserpyna Study).
Calegari MA, Zurlo IV, Dell'Aquila E, Basso M, Orlandi A, Bensi M, Camarda F, Anghelone A, Pozzo C, Sperduti I, Salvatore L, Santini D, Corsi DC, Bria E, Tortora G. Calegari MA, et al. Among authors: zurlo iv. Clin Colorectal Cancer. 2024 Jun 12:S1533-0028(24)00057-4. doi: 10.1016/j.clcc.2024.06.002. Online ahead of print. Clin Colorectal Cancer. 2024. PMID: 38969549
Efficacy of Regorafenib and Trifluridine/Tipiracil According to Extended RAS Evaluation in Advanced Metastatic Colorectal Cancer Patients: A Multicenter Retrospective Analysis.
Basso M, Signorelli C, Calegari MA, Lucchetti J, Zurlo IV, Dell'Aquila E, Arrivi G, Zoratto F, Santamaria F, Saltarelli R, Trovato G, Caira G, Angotti L, Schirripa M, Anghelone A, Schietroma F, Chilelli MG, Salvatore L, Pozzo C, Tortora G. Basso M, et al. Among authors: zurlo iv. Target Oncol. 2024 May;19(3):371-382. doi: 10.1007/s11523-024-01050-3. Epub 2024 Apr 13. Target Oncol. 2024. PMID: 38613732 Free PMC article.
Extrapulmonary Neuroendocrine Carcinomas: Current Management and Future Perspectives.
Stumpo S, Formelli MG, Persano I, Parlagreco E, Lauricella E, Rodriquenz MG, Guerrera LP, Zurlo IV, Campana D, Brizzi MP, Cives M, La Salvia A, Lamberti G. Stumpo S, et al. Among authors: zurlo iv. J Clin Med. 2023 Dec 15;12(24):7715. doi: 10.3390/jcm12247715. J Clin Med. 2023. PMID: 38137784 Free PMC article. Review.
Retrospective Correlation between First Drug Treatment Duration and Survival Outcomes in Sequential Treatment with Regorafenib and Trifluridine/Tipiracil in Refractory Metastatic Colorectal Cancer: A Real-World Subgroup Analysis.
Signorelli C, Chilelli MG, Giannarelli D, Basso M, Calegari MA, Anghelone A, Lucchetti J, Minelli A, Angotti L, Zurlo IV, Schirripa M, Morelli C, Dell'Aquila E, Cosimati A, Gemma D, Ribelli M, Emiliani A, Corsi DC, Arrivi G, Mazzuca F, Zoratto F, Morandi MG, Santamaria F, Saltarelli R, Ruggeri EM. Signorelli C, et al. Among authors: zurlo iv. Cancers (Basel). 2023 Dec 8;15(24):5758. doi: 10.3390/cancers15245758. Cancers (Basel). 2023. PMID: 38136304 Free PMC article.
Treatment Settings and Outcomes with Regorafenib and Trifluridine/Tipiracil at Third-Line Treatment and beyond in Metastatic Colorectal Cancer: A Real-World Multicenter Retrospective Study.
Signorelli C, Calegari MA, Basso M, Anghelone A, Lucchetti J, Minelli A, Angotti L, Zurlo IV, Schirripa M, Chilelli MG, Morelli C, Dell'Aquila E, Cosimati A, Gemma D, Ribelli M, Emiliani A, Corsi DC, Arrivi G, Mazzuca F, Zoratto F, Morandi MG, Santamaria F, Saltarelli R, Ruggeri EM. Signorelli C, et al. Among authors: zurlo iv. Curr Oncol. 2023 Jun 4;30(6):5456-5469. doi: 10.3390/curroncol30060413. Curr Oncol. 2023. PMID: 37366896 Free PMC article.
Efficacy of third-line anti-EGFR-based treatment versus regorafenib or trifluridine/tipiracil according to primary tumor site in RAS/BRAF wild-type metastatic colorectal cancer patients.
Salvatore L, Bensi M, Vivolo R, Zurlo IV, Dell'Aquila E, Grande R, Anghelone A, Emiliani A, Citarella F, Calegari MA, Ribelli M, Basso M, Pozzo C, Tortora G. Salvatore L, et al. Among authors: zurlo iv. Front Oncol. 2023 Feb 21;13:1125013. doi: 10.3389/fonc.2023.1125013. eCollection 2023. Front Oncol. 2023. PMID: 36895480 Free PMC article.
Codon-specific KRAS mutations predict survival benefit of trifluridine/tipiracil in metastatic colorectal cancer.
van de Haar J, Ma X, Ooft SN, van der Helm PW, Hoes LR, Mainardi S, Pinato DJ, Sun K, Salvatore L, Tortora G, Zurlo IV, Leo S, Giampieri R, Berardi R, Gelsomino F, Merz V, Mazzuca F, Antonuzzo L, Rosati G, Stavraka C, Ross P, Rodriquenz MG, Pavarana M, Messina C, Iveson T, Zoratto F, Thomas A, Fenocchio E, Ratti M, Depetris I, Cergnul M, Morelli C, Libertini M, Parisi A, De Tursi M, Zanaletti N, Garrone O, Graham J, Longarini R, Gobba SM, Petrillo A, Tamburini E, La Verde N, Petrelli F, Ricci V, Wessels LFA, Ghidini M, Cortellini A, Voest EE, Valeri N. van de Haar J, et al. Among authors: zurlo iv. Nat Med. 2023 Mar;29(3):605-614. doi: 10.1038/s41591-023-02240-8. Epub 2023 Mar 2. Nat Med. 2023. PMID: 36864254 Free PMC article. Clinical Trial.
21 results